Gsk Plc · LSE:GSK
Gsk — Cowen 37th Annual Healthcare Conference (March 2017)
17 slides from Gsk's conference presentation, Mar 8, 2017
Slide 1: GSK Oncology
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 2017
Slide 2: Oncology R&D Strategy
Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics Reprogram cancer Long-term survival & cells cures Stimulate anti-tumour GSK pipeline immunity Cells as medicines Immuno-Oncology First-in-class medicines Combination therapy Cell & Gene T
Slide 3: Main Trends
Main Trends SOC Immune New replacements profiling technologies Elimination of chemotherapy Patient selection Expansion of the from SOC to predict toolbox regimens response Today CURE Substantial survival Complex improvements combinations Across wide Maximise efficacy populations Improved endpoints A
Slide 4: Oncology – Pipeline Snapshot
Oncology – Pipeline Snapshot Mechanism Pre-clinical Phase I Phase II OX40 agonist (GSK3174998) † Solid tumours, Heme Malignancies ICOS agonist (GSK3359609) † Solid tumours BCMA ADC (GSK 2857916) † Multiple Myeloma TLR4 agonist (GSK1795091) Cancer Novel small molecule targets Immuno-Oncology ImmTacs
Slide 5: Immuno-Oncology: Generations of Therapies
Immuno-Oncology: 3 Generations of Therapies Generation 1 Generation 2 Generation 3 TECENTRIQ Multiple therapies atezolizumab (PD-L1) under YERVOY KEYTRUDA development ipilimumab (CTLA-4) pembrolizumab (PD-1) 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 PROVENGE BLINCYTO sipuleucel-T blinatumoma
Slide 6: 3rd Generation Opportunities
3rd Generation Opportunities Spectrum of immuno-oncology modalities Adaptive Immunity Innate Immunity T-Cell Immunity B-Cell Immunity Cytokines Cellular Therapies - NK Cells Cancer Vaccines T-cell Checkpoint Modulators Checkpoint Modulators “Connector” Bi-specific Abs - Dual-specific Abs Small Molec
Slide 7: 3rd Generation Opportunities: GSK's multi-modality pipeline
3rd Generation Opportunities GSK’s multi-modality pipeline Adaptive Immunity Innate Immunity T-Cell Immunity B-Cell Immunity Cytokines Cellular Therapies - NK Cells* Cancer Vaccines T-cell Checkpoint Modulators Checkpoint Modulators “Connector” Bi-specific Abs - Dual-specific Abs Small Molecules Onc
Slide 8: GSK2857916: First-in-class anti-BCMA-ADC, proof of concept in multiple myeloma
GSK2857916: First-in-class anti-BCMA-ADC, proof of concept in multiple myeloma All doses: ORR = 8/30 (27%; 95% CI: 12.3%, 45.9%) At >Ph2 dose 3.4 mg/kg: ORR= 6/9 (66.7%; 95% CI: 0.29, 0.92%) B Cell maturation antigen (BCMA) High-expression target in multiple myeloma and some NHL Phase I data present
Slide 9: GSK3174998 OX40 agonist mAb
GSK3174998 OX40 agonist mAb Survival in animal model (CT26) OX-40 + PD-1 GSK3174998 is one of several OX-40s in clinic 100 Percent survival 80 Dual mechanism: enhancing effector T-cell and 60 aOX40 /aPD-1 suppressing T-regs 40 20 aOX40 Collaboration with MD Anderson control aPD-1 0 20 30 40 50 60 70
Slide 10: GSK3359609 First-in-class ICOS agonist mAb
GSK3359609 First-in-class ICOS agonist mAb ICOS in ipilimumab-treated patients GSK3359609 Uniquely engineered IgG4 mAb with agonist function and no cell depletion 80 CD4 ICOS T cells T cell Activation in-vitro Cell count/L % of total CD4 T cells 100 CD69+ CD4 T cells 24hr after stimulation 60 80 Ev
Slide 11: GSK1795091: TLR4 agonist
GSK1795091: TLR4 agonist Pre-clinical combination synergy Glycolipid TLR-4 agonist compound TLR4 + OX40 Activates dendritic cells and innate immunity, positively modulates tumour microenvironment Strong combination potential with several IO agents Potential mechanistic synergies with OX40 and TLR4 +
Slide 12: NY-ESO-1 TCR-T Cell Therapy
NY-ESO-1 TCR-T Cell Therapy Sarcoma Phase I/II: Individual patient complete response (CR) TCR T-cell therapy Baseline Day 2: Inflammation Day 100: CR 50% ORR in synovial sarcoma Ongoing studies in myeloma, ovarian cancer and other solid tumours 60 Sarcoma Phase I/II: Best response in treated patient
Slide 13: Partnerships
Partnerships GSK partnerships in Cell Therapy and Clinical Translational Research Cell Therapy Oncology Clinical & Translational Consortium And others… 13
Slide 14: Epigenetics clinical programs
Epigenetics clinical programs Dhanak et al Nature, 2013 EZH2 LSD1 BET PRMT5 14
Slide 15: GSK525762: BET inhibitor
GSK525762: BET inhibitor Broad activity across multiple tumor types – preclinical cell line models ‘762 Blocks binding of BET family proteins (BRD2, 3 and 4) to acetylated histones causing targeted changes in gene expression including oncogene silencing Preclinical data: Activity of GSK525762 in man
Slide 16: GSK525762: Potential First-in-class BET Inhibitor
GSK525762: Potential First-in-class BET Inhibitor Early clinical efficacy in NMC; Progress in many tumour types Spider plot of % change from baseline in target lesion diameter Preliminary evidence of clinical activity in 100 NUT midline carcinoma (NMC) (AACR 2016) 80 † 60 •Across all dose cohort (n=
Slide 17: Oncology at GSK
Oncology at GSK Mission: Maximise patient survival Achieve a long-term leadership position in Oncology Scientific Focus Tactics Goals • Optimise T-cell Immunity • Diversified pipeline • Transformational effects for • Across key modalities patients • Re-program cancer cells • Maximise survival • Inno
GSK — Cowen 37th Annual Healthcare Conference (March 2017) on 6ix